US 12,458,683 B2
Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use
Michael J. Lenardo, Bethesda, MD (US); Jian Li, Rockville, MD (US); Lixin Zheng, Rockville, MD (US); Jae W. Lee, Philadelphia, PA (US); and Wei Lu, Rockville, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The United States of America, as represented by the Secretary, Department of Health & Human Services, Rockville, MD (US)
Filed on Jul. 21, 2020, as Appl. No. 16/934,573.
Application 16/934,573 is a continuation in part of application No. 15/556,738, granted, now 10,759,838, previously published as PCT/US2016/021571, filed on Mar. 9, 2016.
Claims priority of provisional application 62/219,851, filed on Sep. 17, 2015.
Claims priority of provisional application 62/130,285, filed on Mar. 9, 2015.
Prior Publication US 2021/0038685 A1, Feb. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 48/00 (2006.01); A61K 38/17 (2006.01); A61P 25/28 (2006.01); C12N 15/62 (2006.01); C12N 15/63 (2006.01)
CPC A61K 38/17 (2013.01) [A61K 48/00 (2013.01); A61P 25/28 (2018.01); C12N 15/62 (2013.01); C12N 15/63 (2013.01); C12N 2320/30 (2013.01)] 9 Claims
 
1. A method of decreasing in a mammal the expression of at least one monocyte or lymphocyte gene selected from the group consisting of CCL8, CCL6, CCL17, and CCL9, the method comprising administering a composition comprising a nucleic acid molecule comprising a nucleotide sequence encoding a fusion protein consisting essentially of a first peptide, a second peptide, and a third peptide, wherein the first peptide consists of SEQ ID NO:1 or 25, the second peptide consists of SEQ ID NO:2 or SEQ ID NO: 28, and the third peptide consists of SEQ ID NO:3.